Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
- PMID: 29361816
- PMCID: PMC6192918
- DOI: 10.4143/crt.2017.552
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
Abstract
Purpose: Alteration of biomarker status after primary systemic therapy (PST) is occasionally found in breast cancer. This study was conducted to clarify the clinical implications of change of biomarker status in breast cancer patients treated with PST.
Materials and methods: The pre-chemotherapeutic biopsy and post-chemotherapeutic resection specimens of 442 breast cancer patients who had residual disease after PST were included in this study. The association between changes of biomarker status after PST and clinicopathologic features of tumors, and survival of the patients, were analyzed.
Results: Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status changed after PST in 18 (4.1%), 80 (18.1%), and 15 (3.4%) patients,respectively. ER and PR mainly underwent positive to negative conversion,whereas HER2 status underwent negative to positive conversion. Negative conversion of ER and PR status after PST was associated with reduced disease-free survival. Moreover, a decline in the Allred score for PR in post-PST specimens was significantly associated with poor clinical outcome of the patients. HER2 change did not have prognostic significance. In multivariate analyses, negative PR status after PST was found to be an independent adverse prognostic factor in the whole patient group, in the adjuvant endocrine therapy-treated subgroup, and also in pre-PST PR positive subgroup.
Conclusion: ER and HER2 status changed little after PST, whereas PR status changed significantly. In particular, negative conversion of PR status was revealed as a poor prognostic indicator, suggesting that re-evaluation of basic biomarkers is mandatory in breast cancer after PST for proper management and prognostication of patients.
Keywords: Biomarkers; Breast neoplasms; Neoadjuvant therapy; Progesterone receptors; Prognosis.
Conflict of interest statement
Conflict of interest relevant to this article was not reported.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6192918/bin/crt-2017-552f1.gif)
![Fig. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6192918/bin/crt-2017-552f2.gif)
![Fig. 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6192918/bin/crt-2017-552f3.gif)
![Fig. 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6192918/bin/crt-2017-552f4.gif)
Similar articles
-
Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.PLoS One. 2021 Mar 5;16(3):e0247802. doi: 10.1371/journal.pone.0247802. eCollection 2021. PLoS One. 2021. PMID: 33667252 Free PMC article.
-
Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.J BUON. 2017 May-Jun;22(2):638-643. J BUON. 2017. PMID: 28730768
-
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x. World J Surg Oncol. 2016. PMID: 27619909 Free PMC article.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
-
Evidence reviews for adjuvant systemic therapy planning: Early and locally advanced breast cancer: diagnosis and management: Evidence review C.London: National Institute for Health and Care Excellence (NICE); 2018 Jul. London: National Institute for Health and Care Excellence (NICE); 2018 Jul. PMID: 35073003 Free Books & Documents. Review.
Cited by
-
Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients.Front Surg. 2023 Jan 6;9:1037215. doi: 10.3389/fsurg.2022.1037215. eCollection 2022. Front Surg. 2023. PMID: 36684294 Free PMC article.
-
Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer.Life (Basel). 2022 Dec 27;13(1):74. doi: 10.3390/life13010074. Life (Basel). 2022. PMID: 36676023 Free PMC article.
-
Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy.Eur Radiol. 2023 Apr;33(4):2965-2974. doi: 10.1007/s00330-022-09264-7. Epub 2022 Nov 23. Eur Radiol. 2023. PMID: 36418622
-
Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study.Ann Transl Med. 2022 Jan;10(2):93. doi: 10.21037/atm-21-6924. Ann Transl Med. 2022. PMID: 35282081 Free PMC article.
-
HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review.World J Clin Cases. 2022 Jan 7;10(1):260-267. doi: 10.12998/wjcc.v10.i1.260. World J Clin Cases. 2022. PMID: 35071526 Free PMC article.
References
-
- Ignatiadis M, Buyse M, Sotiriou C. St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists. Ann Oncol. 2015;26:1519–20. - PubMed
-
- Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v8–30. - PubMed
-
- Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg. 2003;186:348–50. - PubMed
-
- Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat. 1999;53:51–9. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous